A Single-Center Experience With En-Bloc Combined Heart+Liver Transplantation: Analysis of Eight Cases, Including Two Heart+Liver+Kidney Transplants
- 9 June 2025
- journal article
- Published by SAGE Publications in World Journal for Pediatric and Congenital Heart Surgery
- Vol. 17 (1) , 106-112
Abstract
Objectives: Review our clinical experience with eight patients at the University of Florida undergoing En-bloc combined heart+liver transplantation (ECH + LTX). Methods: Continuous variables are reported as median (interquartile range = IQR) and categorical variables are reported as N (%). Results: Eight patients underwent ECH + LTX between August 2020 and May 2023 at the University of Florida, with triple heart+liver+kidney transplantation performed in 2/8 = 25%. Median age at ECH + LTX was 47.34 years (IQR = 33.66-53.37), and all eight patients were >18 years of age. Six out of eight patients (75%) had congenital heart disease (CHD): one had biventricular CHD and five had functionally univentricular circulation and Fontan failure. Two out of eight patients (25%) had structurally normal hearts and acquired heart disease: one patient with hemochromatosis and combined cardiac and hepatic failure with nonischemic restrictive cardiomyopathy and one patient with nonischemic cardiomyopathy and alcoholic cirrhosis. Median wait list time was 93 days (IQR = 27.50-176.25). Three patients (3/8 = 37.5%) were supported with an intra-aortic balloon pump prior to ECH + LTX, and two of these three patients were subsequently also supported with extracorporeal membrane oxygenation secondary to progressive decompensation prior to ECH + LTX. Median hospital length of stay was 147 days. Median posttransplant length of stay was of 29 days. Seven of eight patients survived ECH + LTX and are alive today. One patient died two days after ECH + LTX. Mean length of follow-up after ECH + LTX of seven surviving patients (years) is 3.60 ± 0.38 (median = 3.79, IQR = 3.05-4.38, range = 1.91-4.64). Conclusion: En-bloc heart-liver transplantation is an effective treatment option for patients with combined heart and liver failure.Keywords
This publication has 18 references indexed in Scilit:
- The Evolution of Combined Heart+Liver TransplantationThe Annals of Thoracic Surgery, 2023
- Clinical Outcomes of Adult Fontan-Associated Liver Disease and Combined Heart-Liver TransplantationJACC, 2023
- An Analysis of 183 Heart Transplants for Pediatric or Congenital Heart Disease—Impact of High Panel Reactive AntibodyThe Annals of Thoracic Surgery, 2022
- Fate of the liver in the survivors of adult heart transplant for a failing Fontan circulationThe Journal of Heart and Lung Transplantation, 2022
- The Epidemiology of Persons Living with Fontan in 2020 and Projections for 2030: Development of an Epidemiology Model Providing Multinational EstimatesAdvances in Therapy, 2021
- Heart-After-Liver Transplantation Attenuates Rejection of Cardiac Allografts in Sensitized PatientsJACC, 2021
- A Review of Heart Transplantation for Adults With Congenital Heart DiseaseJournal of Cardiothoracic and Vascular Anesthesia, 2021
- En Bloc Combined Heart and Liver Transplantation for End-Stage Heart FailureOperative Techniques in Thoracic and Cardiovascular Surgery, 2021
- En-Bloc Simultaneous Heart–Liver Transplantation in Adult PatientsAnnals of Surgery, 2020
- Fontan-associated liver disease: pathophysiology, investigations, predictors of severity and managementEuropean Journal of Gastroenterology & Hepatology, 2019